menu
    • menu
    [{"orgOrder":0,"company":"Bellerophon Pulse Technologies","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bellerophon Pulse Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellerophon Pulse Technologies \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Pulse Technologies \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Neurology","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Neurology","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"RUSSIA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"RUSSIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Superficial Siderosis Research Alliance Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Hematology","graph2":"Undisclosed","graph3":"Superficial Siderosis Research Alliance Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Superficial Siderosis Research Alliance Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Superficial Siderosis Research Alliance Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Michael Alan Schwarzschild","sponsor":"Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Neurology","graph2":"Phase III","graph3":"Michael Alan Schwarzschild","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Michael Alan Schwarzschild \/ Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Michael Alan Schwarzschild \/ Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke"}]

    Find Clinical Drug Pipeline Developments & Deals for (-)-Inosine

    Menu

    (-)-Inosine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytoflavin in the Complex Rehabilitation of Stroke Patients

                            Details : Inosine is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 07, 2023

                            Lead Product(s) : Inosine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Superficial Siderosis Research Alliance Inc.

                            Country arrow
                            AAPS
                            Not Confirmed

                            Superficial Siderosis Research Alliance Inc.

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Antioxidant Supplementation

                            Details : Inosine is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Siderosis.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            May 18, 2021

                            Lead Product(s) : Inosine

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy

                            Details : Inosine is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Neuropathies.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 02, 2020

                            Lead Product(s) : Inosine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            International Trial of Efficacy of Cytoflavin in Head Trauma

                            Details : Inosine is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Head Injuries, Closed.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : Inosine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After M...

                            Details : Inosine is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            February 21, 2019

                            Lead Product(s) : Inosine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bellerophon Pulse Technologies

                            Country arrow
                            AAPS
                            Not Confirmed

                            Bellerophon Pulse Technologies

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled...

                            Details : INO is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 27, 2018

                            Lead Product(s) : Inosine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed

                            Polysan

                            Russia arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

                            Details : Runihol (Inosine) is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Runihol

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            October 12, 2016

                            Lead Product(s) : Inosine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Michael Alan Schwarzschild

                            Country arrow
                            AAPS
                            Not Confirmed

                            Michael Alan Schwarzschild

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inosine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Urate Elevation in Parkinson's Disease, Phase 3

                            Details : Inosine is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 30, 2015

                            Lead Product(s) : Inosine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Parkinson Study Group | Michael J. Fox Foundation | University of Rochester | National Institute of Neurological Disorders and Stroke

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth